Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB/Sanofi’s Xyzal Clears FDA As Once-Daily Antihistamine

This article was originally published in The Pink Sheet Daily

Executive Summary

Xyzal will be available for the fall allergy season after being approved for symptoms associated with seasonal and perennial allergic rhinitis.
Advertisement

Related Content

Generic Keppra Set For Launch In November 2008 After UCB Settles
Generic Keppra Set For Launch In November 2008 After UCB Settles
UCB’s Next Allergy Partner Is Sanofi-Aventis
UCB’s Next Allergy Partner Is Sanofi-Aventis

Topics

Advertisement
UsernamePublicRestriction

Register

PS066103

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel